Literature DB >> 6312082

Genetic and phenotypic analysis of herpes simplex virus type 1 mutants conditionally resistant to immune cytolysis.

B A Pancake, D P Aschman, P A Schaffer.   

Abstract

Nine temperature-sensitive (ts) mutants of herpes simplex virus type 1 selected for their inability to render cells susceptible to immune cytolysis after infection at the nonpermissive temperature have been characterized genetically and phenotypically. The mutations in four mutants were mapped physically by marker rescue and assigned to functional groups by complementation analysis. In an effort to determine the molecular basis for cytolysis resistance, cells infected with each of the nine mutants were monitored for the synthesis of viral glycoprotein in total cell extracts and for the presence of these glycoproteins in plasma membranes. The four mutants whose ts mutations were mapped were selected with polypeptide-specific antiserum to glycoproteins gA and gB; however, three of the four mutations mapped to DNA sequences outside the limits of the structural gene specifying these glycoproteins. Combined complementation and phenotypic analysis indicates that the fourth mutation also lies elsewhere. The ts mutations in five additional cytolysis-resistant mutants could not be rescued with single cloned DNA fragments representing the entire herpes simplex virus type 1 genome, suggesting that these mutants may possess multiple mutations. Complementation tests with the four mutants whose ts lesions had been mapped physically demonstrated that each represents a new viral gene. Examination of mutant-infected cells at the nonpermissive temperature for the presence of viral glycoproteins in total cell extracts and in membranes at the cell surface demonstrated that (i) none of the five major viral glycoproteins was detected in extracts of cells infected with one mutant, suggesting that this mutant is defective in a very early function; (ii) cells infected with six of the nine mutants exhibited greatly reduced levels of all the major viral glycoproteins at the infected cell surface, indicating that these mutants possess defects in the synthesis or processing of viral glycoproteins; and (iii) in cells infected with one mutant, all viral glycoproteins were precipitable at the surface of the infected cell, despite the resistance of these cells to cytolysis. This mutant is most likely mutated in a gene affecting a late stage in glycoprotein processing, leading to altered presentation of glycoproteins at the plasma membrane. The finding that the synthesis of both gB and gC was affected coordinately in cells infected with six of the nine mutants suggests that synthesis of these two glycoproteins, their transport to the cell surface, or their insertion into plasma membranes is coordinately regulated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6312082      PMCID: PMC255298     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  DNA synthesis and DNA polymerase activity of herpes simplex virus type 1 temperature-sensitive mutants.

Authors:  G M Aron; D J Purifoy; P A Schaffer
Journal:  J Virol       Date:  1975-09       Impact factor: 5.103

2.  Intertypic complementation and recombination between temperature-sensitive mutants of herpes simplex virus types 1 and 2.

Authors:  J Esparza; B Benyesh-Melnick; P A Schaffer
Journal:  Virology       Date:  1976-04       Impact factor: 3.616

3.  Membrane proteins specified by herpes simplex viruses. I. Identification of four glycoprotein precursors and their products in type 1-infected cells.

Authors:  P G Spear
Journal:  J Virol       Date:  1976-03       Impact factor: 5.103

4.  Structure and function of herpesvirus genomes. II. EcoRl, Sbal, and HindIII endonuclease cleavage sites on herpes simplex virus.

Authors:  J Skare; W C Summers
Journal:  Virology       Date:  1977-02       Impact factor: 3.616

5.  Some properties of recombinants between type 1 and type 2 herpes simplex viruses.

Authors:  I W Halliburton; R E Randall; R A Killington; D H Watson
Journal:  J Gen Virol       Date:  1977-09       Impact factor: 3.891

6.  Synthesis of virus-specific polypaptides by temperature-sensitive mutants of herpes simplex virus type 1.

Authors:  R J Courtney; P A Schaffer; K L Powell
Journal:  Virology       Date:  1976-12       Impact factor: 3.616

7.  Genetic studies with herpes simplex virus type 1. The isolation of temperature-sensitive mutants, their arrangement into complementation groups and recombination analysis leading to a linkage map.

Authors:  S M Brown; D A Ritchie; J H Subak-Sharpe
Journal:  J Gen Virol       Date:  1973-03       Impact factor: 3.891

8.  Temperature-sensitive mutants of herpes simplex virus type 1: isolation, complementation and partial characterization.

Authors:  P A Schaffer; G M Aron; N Biswal; M Benyesh-Melnick
Journal:  Virology       Date:  1973-03       Impact factor: 3.616

9.  A temperature-sensitive mutant of herpes simplex virus defective in glycoprotein synthesis.

Authors:  P A Schaffer; R J Courtney; R M McCombs; M Benyesh-Melnick
Journal:  Virology       Date:  1971-11       Impact factor: 3.616

10.  Anatomy of herpes simplex virus DNA. IX. Apparent exclusion of some parental DNA arrangements in the generation of intertypic (HSV-1 X HSV-2) recombinants.

Authors:  L S Morse; T G Buchman; B Roizman; P A Schaffer
Journal:  J Virol       Date:  1977-10       Impact factor: 5.103

View more
  21 in total

1.  Analysis of the gB promoter of herpes simplex virus type 1: high-level expression requires both an 89-base-pair promoter fragment and a nontranslated leader sequence.

Authors:  N E Pederson; S Person; F L Homa
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

2.  Overexpression in bacterial and identification in infected cells of the pseudorabies virus protein homologous to herpes simplex virus type 1 ICP18.5.

Authors:  N E Pederson; L W Enquist
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

3.  Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1.

Authors:  Y E Chang; A P Poon; B Roizman
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

4.  The nucleotide sequence of a pseudorabies virus gene similar to ICP18.5 of herpes simplex virus type 1.

Authors:  N E Pederson; L W Enquist
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

5.  Anatomy of the herpes simplex virus 1 strain F glycoprotein B gene: primary sequence and predicted protein structure of the wild type and of monoclonal antibody-resistant mutants.

Authors:  P E Pellett; K G Kousoulas; L Pereira; B Roizman
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

6.  Cross-reactivity between herpes simplex virus glycoprotein B and a 63,000-dalton varicella-zoster virus envelope glycoprotein.

Authors:  C M Edson; B A Hosler; R A Respess; D J Waters; D A Thorley-Lawson
Journal:  J Virol       Date:  1985-10       Impact factor: 5.103

7.  Transcription initiation sites and nucleotide sequence of a herpes simplex virus 1 gene conserved in the Epstein-Barr virus genome and reported to affect the transport of viral glycoproteins.

Authors:  P E Pellett; F J Jenkins; M Ackermann; M Sarmiento; B Roizman
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

8.  The pseudorabies virus UL28 protein enters the nucleus after coexpression with the herpes simplex virus UL15 protein.

Authors:  K M Koslowski; P R Shaver; X Y Wang; D J Tenney; N E Pederson
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

9.  Pseudorabies virus mutants lacking the essential glycoprotein gII can be complemented by glycoprotein gI of bovine herpesvirus 1.

Authors:  I Rauh; F Weiland; F Fehler; G M Keil; T C Mettenleiter
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

10.  Herpesvirus ICP18.5 and DNA-binding protein genes are conserved in equine herpesvirus-1.

Authors:  C W Bell; J M Whalley
Journal:  Virus Genes       Date:  1993-09       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.